Skip to main content

Develop Novel Medicines for Once Monthly Intranasal Administration Designed to Mitigate Clinical Symptoms Associated With Respiratory Diseases

Printer-friendly versionPrinter-friendly versionSend by emailSend by email
Award date: 
Sep 11, 2015
Award amount: 
$150,000
Organization name: 
Symmune Therapeutics, LLC
Principal Investigator: 
Lyman, Scott
Grant program category: 
Business Financing
Grant program name: 
Small Business Research Loan
Region: 
Research Triangle

Symmune Therapeutics, based in Durham, is developing immune based treatments for respiratory diseases. The company was awarded $150,000 to support research and development of a new type of probiotic treatment for chronic asthma and respiratory allerges.

Fiscal year: 
2016